A new report from the American Cancer Society Cancer Action Network (ACS CAN) takes an in-depth look at disparities across all areas of cancer research and suggests immediate policy solutions that could help address such gaps in the years to come.
Cancer Research Groups Push Emergency Funding to Restart Clinical Trials in Infrastructure Package
Estimated $10 Billion Necessary to Recoup Pandemic-Related Costs and Delays
Washington, D.C.—A group of more than fifty cancer research-focused organizations are urging Congress to include $10 billion in emergency funding to restart cancer research and clinical trials at the National Institutes of Health (NIH) stalled by the coronavirus pandemic. In a letter sent to lawmakers, members of the One Voice Against Cancer Coalition say without the additional resources in the forthcoming American Jobs Plan, promising research will languish and potentially be lost entirely.
A statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network, follows:
“The pandemic’s impact on cancer research has been severe. Early shutdowns forced research to come to an abrupt halt, and restarting trials has required implementing new protocols, procuring personal protective equipment and sometimes restarting work altogether that otherwise could not be resumed. The cost of these disruptions has been significant and threatens to jeopardize progress in the effort to reduce our country’s cancer burden for years to come.
“Clinical trials are often the best and sometimes only course of treatment for patients in need of care. On behalf of all cancer patients, survivors and their families, we urge Congress to include this additional NIH funding in the American Jobs Plan and ensure medical research can keep moving forward without delay.”